Phase 1, Dose Escalation, Nonrandomized, Open-Label, Clinical Trial Evaluating the Safety and Preliminary Efficacy of Allogenic Adipose-Derived Mesenchymal Stem Cells for Recurrent Glioblastoma: A Clinical Trial Protocol
Authors:
- Andres Ramos-FresnedoARAndres Ramos-Fresnedo
- Rawan Al-KharbooshRARawan Al-Kharboosh
- Erin L. TwohyETErin L. Twohy
- Aleeshba N. BasilABAleeshba N. Basil
- Ewa C. SzymkiewiczESEwa C. Szymkiewicz
- Abba C. ZubairAZAbba C. Zubair
- Daniel M. TrifilettiDTDaniel M. Trifiletti
- Nisha DurandNDNisha Durand
- Dennis W. DicksonDDDennis W. Dickson
- Erik H. MiddlebrooksEMErik H. Middlebrooks
- David N. AbarbanelDADavid N. Abarbanel
- Stephany Y. TzengSTStephany Y. Tzeng
Open Access
- 13 October 2023
- journal article
- Published by Wolters Kluwer Health in Neurosurgery Practice
- Vol. 4 (4)
Abstract
BACKGROUND AND OBJECTIVES: Despite standard of care with maximal safe resection and chemoradiation, glioblastoma (GBM) is the most common and aggressive type of primary brain cancer. Surgical resection provides a window of opportunity to locally treat gliomas while the patient is recovering and before initiating concomitant chemoradiation. The objective was to assess the safety and establish the maximum tolerated dose of adipose-derived mesenchymal stem cells (AMSCs) for the treatment of recurrent GBM. Secondary objectives were to assess the toxicity profile and long-term survival outcomes of patients enrolled in the trial. In addition, biospecimens will be collected to explore the local and systemic responses to this therapy. METHODS: We will conduct a phase 1, dose-escalated, nonrandomized, open-label, clinical trial of patients with GBM who are undergoing surgical resection for recurrence. Up to 18 patients will receive intracavitary application of AMSCs encapsulated in fibrin glue during surgical resection. All patients will be followed for up to 5 years for safety and survival data. Adverse events will be recorded using the CTCAE V5.0. EXPECTED OUTCOMES: This study will explore the maximum tolerated dose of AMSCs along with the toxicity profile of this therapy in patients with recurrent GBM. In addition, preliminary long-term survival and progression-free survival outcome analysis will be used to power further randomized studies. Finally, cerebrospinal fluid and blood will be obtained throughout the treatment period to investigate circulating molecular and inflammatory tumoral/stem cell markers and explore the mechanism of action of the therapeutic intervention. DISCUSSION: This prospective translational study will determine the initial safety and toxicity profile of local delivery of AMSCs for recurrent GBM. It will also provide additional survival metrics for future randomized trials.Keywords
Funding Information
- National Cancer Institute (R01CA195503)
- National Cancer Institute (R01CA183827)
This publication has 46 references indexed in Scilit:
- Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in gliomaNature Medicine, 2006
- Increased Regulatory T-Cell Fraction Amidst a Diminished CD4 Compartment Explains Cellular Immune Defects in Patients with Malignant GliomaCancer Research, 2006
- MGMTGene Silencing and Benefit from Temozolomide in GlioblastomaNew England Journal of Medicine, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Targeted therapy for brain tumoursNature Reviews Drug Discovery, 2004
- Brain TumorsNew England Journal of Medicine, 2001
- Glioblastoma multiforme: The terminatorProceedings of the National Academy of Sciences, 2000
- The blood-brain and blood-tumor barriers: A review of strategies for increasing drug deliveryNeuro-Oncology, 2000
- Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomasJournal of Neurosurgery, 1991
- The spread of glioblastoma multiforme as a determining factor in the radiation treated volumeInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1976